VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy
Angiogenesis has been targeted in retinopathies, psoriasis, and a variety of cancers (colon, breast, lung, and kidney). Among these tumour types, clear cell renal cell carcinomas (RCCs) are the most vascularized tumours due to mutations of the von Hippel Lindau gene resulting in HIF-1 alpha stabilis...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Nucleic Acids |
| Online Access: | http://dx.doi.org/10.1155/2012/162692 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561903656763392 |
|---|---|
| author | Caroline Hilmi Mélanie Guyot Gilles Pagès |
| author_facet | Caroline Hilmi Mélanie Guyot Gilles Pagès |
| author_sort | Caroline Hilmi |
| collection | DOAJ |
| description | Angiogenesis has been targeted in retinopathies, psoriasis, and a variety of cancers (colon, breast, lung, and kidney). Among these tumour types, clear cell renal cell carcinomas (RCCs) are the most vascularized tumours due to mutations of the von Hippel Lindau gene resulting in HIF-1 alpha stabilisation and overexpression of Vascular Endothelial Growth Factor (VEGF). Surgical nephrectomy remains the most efficient curative treatment for patients with noninvasive disease, while VEGF targeting has resulted in varying degrees of success for treating metastatic disease. VEGF pre-mRNA undergoes alternative splicing generating pro-angiogenic isoforms. However, the recent identification of novel splice variants of VEGF with anti-angiogenic properties has provided some insight for the lack of current treatment efficacy. Here we discuss an explanation for the relapse to anti-angiogenesis treatment as being due to either an initial or acquired resistance to the therapy. We also discuss targeting angiogenesis via SR (serine/arginine-rich) proteins implicated in VEGF splicing. |
| format | Article |
| id | doaj-art-3498654ad96f4513b686b4f5f3b59401 |
| institution | Kabale University |
| issn | 2090-0201 2090-021X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Nucleic Acids |
| spelling | doaj-art-3498654ad96f4513b686b4f5f3b594012025-02-03T01:23:55ZengWileyJournal of Nucleic Acids2090-02012090-021X2012-01-01201210.1155/2012/162692162692VEGF Spliced Variants: Possible Role of Anti-Angiogenesis TherapyCaroline Hilmi0Mélanie Guyot1Gilles Pagès2University of Nice Sophia Antipolis, Institute of Development and Cancer Research, UMR CNRS 6543, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, FranceUniversity of Nice Sophia Antipolis, Institute of Development and Cancer Research, UMR CNRS 6543, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, FranceUniversity of Nice Sophia Antipolis, Institute of Development and Cancer Research, UMR CNRS 6543, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, FranceAngiogenesis has been targeted in retinopathies, psoriasis, and a variety of cancers (colon, breast, lung, and kidney). Among these tumour types, clear cell renal cell carcinomas (RCCs) are the most vascularized tumours due to mutations of the von Hippel Lindau gene resulting in HIF-1 alpha stabilisation and overexpression of Vascular Endothelial Growth Factor (VEGF). Surgical nephrectomy remains the most efficient curative treatment for patients with noninvasive disease, while VEGF targeting has resulted in varying degrees of success for treating metastatic disease. VEGF pre-mRNA undergoes alternative splicing generating pro-angiogenic isoforms. However, the recent identification of novel splice variants of VEGF with anti-angiogenic properties has provided some insight for the lack of current treatment efficacy. Here we discuss an explanation for the relapse to anti-angiogenesis treatment as being due to either an initial or acquired resistance to the therapy. We also discuss targeting angiogenesis via SR (serine/arginine-rich) proteins implicated in VEGF splicing.http://dx.doi.org/10.1155/2012/162692 |
| spellingShingle | Caroline Hilmi Mélanie Guyot Gilles Pagès VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy Journal of Nucleic Acids |
| title | VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy |
| title_full | VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy |
| title_fullStr | VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy |
| title_full_unstemmed | VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy |
| title_short | VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy |
| title_sort | vegf spliced variants possible role of anti angiogenesis therapy |
| url | http://dx.doi.org/10.1155/2012/162692 |
| work_keys_str_mv | AT carolinehilmi vegfsplicedvariantspossibleroleofantiangiogenesistherapy AT melanieguyot vegfsplicedvariantspossibleroleofantiangiogenesistherapy AT gillespages vegfsplicedvariantspossibleroleofantiangiogenesistherapy |